Literature DB >> 32410379

Reconstructive therapy for the management of peri-implantitis via submerged guided bone regeneration: A prospective case series.

Alberto Monje1, Ramón Pons1, Andrea Roccuzzo2,3, Giovanni E Salvi2, José Nart1.   

Abstract

BACKGROUND: The present case series assesses the response to reconstructive therapy for the management of 2/3-wall peri-implantitis bone defects following submerged-healing guided bone regeneration.
MATERIAL AND METHODS: Fifteen consecutive patients with 27 implants presenting peri-implantitis were included. Guided bone regeneration was applied by means of autogenous bone/deproteinized bovine bone mineral grafting mixture and collagen membrane. Patients were assessed at baseline (T0) and at 6 (T1) and 12 months (T2). Clinical and radiographic variables defined the composite success criteria (probing pocket depth [PPD] ≤ 5 mm, no bleeding on probing/suppuration (SUP), no further radiographic bone loss). Patient site-specific comfort was scored using a visual analog scale (VAS). Descriptive statistics was carried out to assess the changes along the study period. Outcomes are reported in terms of mean values (5%-95% percentile values).
RESULTS: All the clinical variables substantially changed from T0 through T2. In particular, PPD decreased 3.7 mm (0.7-5.9) from T0 to T2. Likewise, the scores for the modified plaque index (mPI) and modified sulcular bleeding index (mBI) were reduced by 0.5 (-0.5-1.1) and 1.6 (0.4-2.4), respectively. SUP did not display at any implant site at T2 (59.2% implants in 29.2% patients suppurated at T0). Keratinized mucosa decreased 0.6 mm (-0.2-4.4) and while mucosal recession increased 2.5 mm (1.0-4.3). Alike, the radiographic parameters varied significantly from T0 through T2. Infrabony defects were filled by 2.2 mm (0.0-8.6) at T2 and marginal bone loss was reduced by 2.3 mm (-1.1-8.1). The mean VAS score significantly increased from T0 (56.7) through T1 to T2, reaching a score of 96 at T2. At this timepoint, 85.2% of the peri-implantitis lesions were resolved.
CONCLUSIONS: The proposed surgical approach followed by submerged healing to reconstruct peri-implant bone defects may offer one therapeutic option for failing dental implants. Given the nature of the present study, its effectiveness in comparison to less invasive treatments needs investigation in randomized controlled trials.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  bone reconstruction; bone regeneration; guided bone regeneration; peri-implant disease; peri-implantitis

Year:  2020        PMID: 32410379     DOI: 10.1111/cid.12913

Source DB:  PubMed          Journal:  Clin Implant Dent Relat Res        ISSN: 1523-0899            Impact factor:   3.932


  4 in total

1.  Incidence of Peri-Implantitis and Relationship with Different Conditions: A Retrospective Study.

Authors:  Víctor Astolfi; Blanca Ríos-Carrasco; Francisco Javier Gil-Mur; José Vicente Ríos-Santos; Beatriz Bullón; Mariano Herrero-Climent; Pedro Bullón
Journal:  Int J Environ Res Public Health       Date:  2022-03-31       Impact factor: 3.390

2.  Efficacy of concentrated growth factor versus collagen membrane in reconstructive surgical therapy of peri-implantitis: 3-year results of a randomized clinical trial.

Authors:  Sila Cagri Isler; Fatma Soysal; Tugce Ceyhanlı; Batuhan Bakırarar; Berrin Unsal
Journal:  Clin Oral Investig       Date:  2022-05-26       Impact factor: 3.606

3.  Non-surgical mechanical therapy of peri-implantitis with or without repeated adjunctive diode laser application. A 6-month double-blinded randomized clinical trial.

Authors:  Andrea Roccuzzo; Sabrina Klossner; Alexandra Stähli; Jean-Claude Imber; Sigrun Eick; Anton Sculean; Giovanni E Salvi
Journal:  Clin Oral Implants Res       Date:  2022-07-10       Impact factor: 5.021

4.  Reconstructive treatment of peri-implantitis infrabony defects of various configurations: 5-year survival and success.

Authors:  Mario Roccuzzo; Davide Mirra; Dario Pittoni; Guglielmo Ramieri; Andrea Roccuzzo
Journal:  Clin Oral Implants Res       Date:  2021-08-16       Impact factor: 5.021

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.